ArticleBMC cardiovascular disorders2025
Clinical significance and regulatory mechanism of miR-134-5p in rheumatic heart disease.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma miR-134-5p: a candidate biomarker for predicting non-response to anti-TNF therapy in rheumatoid arthritis.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic heart disease (RHD) causes irreversible valvular injury and mortality globally. Easily detectable miRNAs may provide valuable perspectives into the clinical management of RHD. This study aimed to explore the role of miR-134-5p in RHD progression.
methodsA total of 167 subjects (80 non-RHD, 87 RHD) were included in this study. The level of miR-134-5p was evaluated by qRT-PCR, and its diagnostic value was assessed by the receiver operator characteristic (ROC) curve. The correlation between miR-134-5p and RHD severity was evaluated by correlation analysis. The association between miR-134-5p expression and RHD prognosis was analyzed by the Kaplan-Meier survival analysis and multivariate COX regression analysis. The regulatory relationship between miR-134-5p and lysine acetyltransferase 7 (KAT7) was assessed by the dual-luciferase reporter assay. In vitro cell experiment was used to assess the regulatory mechanism of miR-134-5p in lipopolysaccharide (LPS)-induced human valvular interstitial cells (hVICs).
resultsUpregulated miR-134-5p in RHD was correlated with RHD severity and could diagnose RHD from rheumatic fever (RF). Low miR-134-5p level was associated with a better prognosis of RHD and could serve as an independent prognostic factor for RHD. Suppression of miR-134-5p in hVICs injury could attenuate the inflammation and oxidative stress by regulating the KAT7 expression.
conclusionsUpregulated miR-134-5p expression showed a diagnostic and prognostic value in RHD. MiR-134-5p may be involved in RHD by regulating the inflammation and oxidative stress in hVIC injury via targeting KAT7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.